Hansa Biopharma AB (HNSA) Stock Statistics & Valuation Metrics

Hansa Biopharma AB has a market cap or net worth of kr1.46B. The enterprise value is kr3.33B.

Hansa Biopharma AB has 67,814,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hansa Biopharma AB’s return on equity (ROE) is 1.37 and return on invested capital (ROIC) is -115.86%.

The current PE Ratio of Hansa Biopharma AB is -3.05. Hansa Biopharma AB’s PEG ratio is 0.16.

In the last 12 months, Hansa Biopharma AB had revenue of 171.32M and earned -806.74M in profits. Earnings per share was -12.84.

In the last 12 months, operating cash flow was -696.65M and capital expenditures -628.00K, giving a free cash flow of -697.28M billion.

Hansa Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Hansa Biopharma AB upcoming earnings date is Jul 17, 2025, TBA Not Confirmed.

Hansa Biopharma AB as a current ratio of 2.29, with Debt / Equity ratio of -163.23%

In the past 12 months, Hansa Biopharma AB has paid 3.03M in taxes.

Hansa Biopharma AB EV to EBITDA ratio is -5.09, with an EV/FCF ratio of -4.27.

Hansa Biopharma AB has kr250.20M in cash and marketable securities with kr1.02B in debt, giving a net cash position of kr767.93M billion.

Gross margin is 52.71%, with operating margin of -372.34%, and net profit margin of -470.91%.

The average price target for Hansa Biopharma AB is kr143.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy